“HiberGene is a company that had hit a classic speedbump where it had developed great products but was not seeing the revenues,” CEO David Corr told The Currency last March. With 13 products in the company’s armoury, including a Covid 19/flu combo test, Corr was optimistic that the experienced executive team behind the medical diagnostics firm could turn the business around. In the wings were investors Des and Brendan O’Farrell, brothers from Meath who had made it big in the US, by setting up successful American diagnostic firms Empirical Bioscience and DCN Dx and now wanted to invest in Ireland. The…

Join The Currency

SPECIAL OFFER.

€1 for 1 month

The Currency has turned 3 – and we are celebrating with a special offer.

Get full access to 3,700 interviews, investigations, columns, features and columns for the first month for just €1.

Or sign up for an annual membership at the reduced price of €200.

Cancel at any time.

To become a member today click here.